Spots Global Cancer Trial Database for lenvatinib
Every month we try and update this database with for lenvatinib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011) | NCT03898180 | Urothelial Carc... | Pembrolizumab Lenvatinib Placebo for len... | 18 Years - | Merck Sharp & Dohme LLC | |
| Immunotherapy With Nivolumab in Combination With Lenvatinib for Advanced Stage Hepatocellular Carcinoma | NCT03841201 | Advanced Hepato... | Lenvatinib Nivolumab | 18 Years - | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | |
| E7080 (Lenvatinib) in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma | NCT01133977 | Stage IV Melano... | Lenvatinib Lenvatinib Dacarbazine | 18 Years - | Eisai Inc. | |
| Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) | NCT03797326 | Advanced Solid ... Triple Negative... Ovarian Cancer Gastric Cancer Colorectal Canc... Glioblastoma Biliary Tract C... Pancreatic Canc... | Pembrolizumab Lenvatinib | 18 Years - | Merck Sharp & Dohme LLC | |
| Lenvatinib and Pembrolizumab Combination Therapy In HPV-associated Recurrent Respiratory Papilloma Patients With Laryngeal, Tracheal, and/or Pulmonary Involvement | NCT04645602 | Human Papilloma... Recurrent Respi... | Lenvatinib Pembrolizumab | 18 Years - | Massachusetts General Hospital | |
| Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001) - China Extension Study | NCT04865289 | Endometrial Neo... | Lenvatinib Pembrolizumab Paclitaxel Carboplatin | 18 Years - | Merck Sharp & Dohme LLC | |
| Toripalimab With or Without Lenvatinib or Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer | NCT06362317 | Biliary Tract N... | Toripalimab Lenvatinib Gemox Chemother... | 18 Years - 75 Years | Peking Union Medical College Hospital | |
| Phase II of Lenvatinib Plus Toripalimab for Advanced HCC | NCT03919383 | Hepatocellular ... | Lenvatinib Toripalimab | 18 Years - 75 Years | Sun Yat-sen University | |
| A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495) | NCT03516981 | Advanced Non-Sm... | Pembrolizumab Favezelimab Lenvatinib Quavonlimab | 18 Years - | Merck Sharp & Dohme LLC | |
| A Study of Belzutifan (MK-6482) as Monotherapy and in Combination With Lenvatinib (E7080/MK-7902) With or Without Pembrolizumab (MK-3475) in China Participants With Advanced Renal Cell Carcinoma (MK-6482-010) | NCT05030506 | Renal Cell Carc... | Belzutifan Pembrolizumab Lenvatinib | 18 Years - | Merck Sharp & Dohme LLC | |
| A Study of Lenvatinib Plus Nivolumab in Participants With Hepatocellular Carcinoma | NCT03418922 | Carcinoma, Hepa... | Lenvatinib Nivolumab | 20 Years - | Eisai Inc. | |
| A Double-Blind Study in Healthy Volunteers to Assess the Effect of E7080 on the QTc Interval | NCT01525394 | Refractory Soli... Lymphomas | Lenvatinib Moxifloxacin 40... Placebos (match... | 18 Years - | Eisai Inc. | |
| Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | NCT04781088 | Platinum-Resist... Platinum-Resist... Platinum-Resist... Recurrent Endom... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... | Lenvatinib Paclitaxel Pembrolizumab | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| SBRT Plus Lenvatinib and TACE for Advanced Primary HCC: A Phase 3 Trial (SEARCH) | NCT05718232 | Advanced Hepato... | Lenvatinib TACE SBRT | 18 Years - 75 Years | Sun Yat-sen University | |
| A Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC) | NCT02657369 | Thyroid Carcino... | Lenvatinib 24 m... | 18 Years - 99 Years | Eisai Inc. | |
| A Study of E7050 in Combination With E7080 in Participants With Advanced Solid Tumors (Dose Escalation) and in Participants With Recurrent Glioblastoma or Unresectable Stage III or Stage IV Melanoma After Prior Systemic Therapy (Expansion Cohort and Phase 2) | NCT01433991 | Advanced Solid ... | Golvatinib Lenvatinib Lenvatinib | 18 Years - | Eisai Inc. | |
| Toripalimab in Combination With Lenvatinib and TACE for Conversion Therapy in Patients With Potentially Resectable HCC | NCT05056337 | Hepatocellular ... | Lenvatinib 4 MG... Toripalimab TACE | 18 Years - 75 Years | Shanghai Zhongshan Hospital | |
| Lenvatinib Combined With Gefitinib in the Treatment of Lenvatinib-resistant Hepatocellular Carcinoma | NCT04642547 | Hepatocellular ... Molecular Targe... | Lenvatinib and ... | 18 Years - 75 Years | RenJi Hospital | |
| Cryoablation Combined With Sintilimab Plus Lenvatinib in 1L Treatment of Advanced ICC (CASTLE-ICC-Chemo-free) | NCT05835245 | Advanced Intrah... | Cryoablation Sintilimab Lenvatinib | 18 Years - | Fudan University | |
| Lenvatinib, Sintilimab Plus SIRT for Unresectable HCC | NCT05992584 | Hepatocellular ... | Lenvatinib, sin... | 18 Years - 75 Years | Second Affiliated Hospital of Guangzhou Medical University | |
| Gender-based Impact on Safety and Efficacy of Lenvatinib in Patients With Differentiated Thyroid Cancer | NCT05789667 | Differentiated ... Gender | Lenvatinib | 18 Years - | Regina Elena Cancer Institute | |
| Efficacy and Safety of Intratumoral Injection of Recombinant Human Adenovirus Type 5 Combined With Tislelizumab and Lenvatinib in the Treatment of Advanced Hepatocellular Carcinoma | NCT06253598 | Hepatocellular ... | Recombinant Hum... Lenvatinib Tislelizumab | 18 Years - 75 Years | First Affiliated Hospital Bengbu Medical College | |
| Capecitabine and Lenvatinib With External Radiation in Rectal Adenocarcinoma | NCT02935309 | Rectal Cancer Rectal Adenocar... | Lenvatinib Capecitabine External Radiat... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Cryoablation Combined With Tislelizumab Plus Lenvatinib in 1L Treatment of Advanced HCC (CASTLE-10) | NCT05897268 | Hepatocellular ... | Cryoablation Tislelizumab Lenvatinib | 18 Years - | Fudan University | |
| Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC) | NCT02973997 | Columnar Cell V... Follicular Vari... Metastatic Thyr... Metastatic Thyr... Poorly Differen... Recurrent Diffe... Recurrent Thyro... Recurrent Thyro... Stage III Diffe... Stage III Thyro... Stage III Thyro... Stage IV Thyroi... Stage IV Thyroi... Stage IVA Diffe... Stage IVA Thyro... Stage IVA Thyro... Stage IVB Diffe... Stage IVB Thyro... Stage IVB Thyro... Stage IVC Diffe... Stage IVC Thyro... Stage IVC Thyro... Tall Cell Varia... Thyroid Gland H... Unresectable Di... Unresectable Th... | Laboratory Biom... Lenvatinib Lenvatinib Mesy... Pembrolizumab | 18 Years - | Academic and Community Cancer Research United | |
| Neoadjuvant Combination Therapy of Lenvatinib and TACE for Transplant-Eligible Large Hepatocellular Carcinoma Patients | NCT05171335 | Hepatocellular ... | Lenvatinib Transcatheter A... | 18 Years - | The Methodist Hospital Research Institute | |
| Envofolimab and Lenvatinib Combined With Gemcitabine Plus Cisplatin for Advanced BTC as First-Line Treatment(ENLIGHTEN) | NCT05410197 | Advanced Biliar... | Envofolimab Lenvatinib Gemcitabine Cisplatin | 18 Years - | Sun Yat-sen University | |
| A Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 Milligram (mg) Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile | NCT02702388 | Thyroid Cancer | Lenvatinib Lenvatinib matc... | 18 Years - | Eisai Inc. | |
| Lenvatinib and Adebrelimab Combined With GEMOX in the Perioperative Treatment of Potentially Resectable Intrahepatic Cholangiocarcinoma | NCT06417606 | Intrahepatic Ch... | Lenvatinib | 18 Years - 80 Years | Tongji Hospital | |
| Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma | NCT05717738 | Hepatocellular ... | TACE Lenvatinib Anti-PD-1 monoc... Bevacizumab Bio... Bevacizumab plu... apatinib plus c... Sorafenib Donafenib Regorafenib | 18 Years - | Tongji Hospital | |
| Study of Avelumab in Combination With Lenvatinib for Children With Primary CNS Tumors | NCT05081180 | Central Nervous... | Avelumab Lenvatinib | 2 Years - 18 Years | EMD Serono | |
| Study of Pembrolizumab, Lenvatinib and Chemotherapy Combination in First Line Extensive-stage Small Cell Lung Cancer | NCT05384015 | Small Cell Lung... | Lenvatinib Pembrolizumab Etoposide Carboplatin | 18 Years - | Fundación GECP | |
| Neoadjuvant Therapy of HAIC（GEMOX） Combined With Adebrelimab and Lenvatinib for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors | NCT06208462 | Intrahepatic Ch... | Adebrelimab Lenvatinib Gemcitabine Oxaliplatin | 18 Years - 75 Years | The First Affiliated Hospital with Nanjing Medical University | |
| Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer | NCT06253494 | Endometrial Can... Cancer of Endom... Carcinoma of En... Endometrial Car... | AdHER2DC vaccin... Pembrolizumab N-803 Lenvatinib PATHWAY HER2 (4... | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| Lenvatinib in Combination With Carboplatin Pemetrexed and Pembrolizumab for NSCLC With EGFR Mutations | NCT05258279 | Non-squamous No... EGFR Activating... | Pembrolizumab Lenvatinib Carboplatin Pemetrexed | 20 Years - | Juntendo University | |
| Pembrolizumab Plus Lenvatinib In Second Line and Third Line Malignant Pleural mesotheLioma Patients | NCT04287829 | Mesotheliomas P... | Pembrolizumab Lenvatinib | 18 Years - | The Netherlands Cancer Institute | |
| Immunotherapy for Advanced Liver Cancer | NCT05033522 | Hepatocellular ... | AlloStim® immun... FOLFOX regimen Sorafenib Lenvatinib | 18 Years - 80 Years | Immunovative Therapies, Ltd. | |
| Expanded Access Program With Lenvatinib for the Treatment of Differentiated Thyroid Cancer in Brazil | NCT03533361 | Thyroid Cancer | Lenvatinib | 18 Years - | Eisai Inc. | |
| A Study Comparing the Combination of the Best Supportive Care Plus E7080 Versus Best Supportive Care Alone, in Patients With Advanced Lung Cancer or Lung Cancer That Has Spread, Who Have Been Previously Treated, Unsuccessfully, With at Least 2 Different Treatments | NCT01529112 | Non-Small Cell ... | Lenvatinib Lenvatinib matc... BSC | 18 Years - | Eisai Inc. | |
| A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma | NCT04039607 | Hepatocellular ... | Nivolumab Ipilimumab Sorafenib lenvatinib | 18 Years - | Bristol-Myers Squibb | |
| Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016) | NCT04976634 | Carcinoma, Hepa... Colorectal Neop... Pancreatic Duct... Biliary Tract N... Endometrial Neo... Esophageal Neop... | Pembrolizumab Belzutifan Lenvatinib | 18 Years - | Merck Sharp & Dohme LLC | |
| Study to Assess the Long-term Safety of Lenvatinib Monotherapy, a Lenvatinib Combination Regimen, or a Comparator Treatment Arm to Cancer Participants in Eisai Sponsored Lenvatinib Trials | NCT03477175 | Solid Tumors | E7080 Comparator Drug Comparator Drug... | 18 Years - | Eisai Inc. | |
| A Phase II Study of AK104 Plus Lenvatinib and TACE in HCC | NCT05319431 | Unresectable, N... | AK104 Lenvatinib TACE | 18 Years - 75 Years | Akeso | |
| Effect of Sarcopenia on HCC After Lenvatinib and Anti-PD-1 Treatment | NCT05443230 | Liver Cancer Sarcopenia | gait speed; ct ... | 18 Years - 80 Years | First Affiliated Hospital of Wenzhou Medical University | |
| Study of Lenvatinib in Combination With Everolimus in Participants With Unresectable Advanced or Metastatic Renal Cell Carcinoma (RCC) | NCT02454478 | Carcinoma, Rena... | Lenvatinib Everolimus | 20 Years - | Eisai Inc. | |
| Neoantigen Derived DCs as Cancer Treatment | NCT05767684 | Refractory Tumo... Solid Tumor | Dendritic Cell ... Lenvatinib Nivolumab | 20 Years - | National Health Research Institutes, Taiwan | |
| Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) (MK-7902-007/E7080-G000-314/LEAP-007) | NCT03829332 | Non-small Cell ... | Pembrolizumab Lenvatinib Placebo for len... | 18 Years - | Merck Sharp & Dohme LLC | |
| A Study to Compare the Efficacy and Safety of Ifosfamide and Etoposide With or Without Lenvatinib in Children, Adolescents and Young Adults With Relapsed and Refractory Osteosarcoma | NCT04154189 | Osteosarcoma | Lenvatinib Ifosfamide Etoposide Lenvatinib | 2 Years - 25 Years | Eisai Inc. | |
| A Study to Evaluate Efficacy and Safety of Lenvatinib Combined With Tislelizumab in Patients With FHRCC | NCT05877820 | Fumarate Hydrat... | Tislelizumab Lenvatinib | 18 Years - 80 Years | RenJi Hospital | |
| Pharmacokinetic Study of E7080/Lenvatinib in Chinese Patients With Unresectable Hepatocellular Carcinoma (HCC) | NCT02953743 | Unresectable He... | Lenvatinib | 18 Years - | Eisai Inc. | |
| HAIC Combined With Lenvatinib and Sintilimab for Hepatocellular Carcinoma With PVTT | NCT04618367 | Carcinoma, Hepa... Liver Neoplasms Sintilimab Portal Vein Tum... | Hepatic arteria... Lenvatinib Sintilimab | 18 Years - 75 Years | Sun Yat-sen University | |
| The Efficacy of Transarterial Chemoinfusion (TAI) Combine Lenvatinib in Advanced Hepatocellular Carcinoma (HCC) | NCT04053985 | Hepatocellular ... | TAI combine len... Lenvatinib | 18 Years - 75 Years | Sun Yat-sen University | |
| Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian Cancer | NCT02788708 | Fallopian Tube ... Recurrent Ovari... Primary Periton... Recurrent Endom... | Lenvatinib Mesy... Paclitaxel Pharmacological... | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Lenvatinib Plus Pembrolizumab In Patients With Immune Checkpoint Inhibitor Naïve Metastatic Uveal Melanoma | NCT05308901 | Melanoma, Uveal | Pembrolizumab Lenvatinib | 18 Years - | Providence Health & Services | |
| Lenvatinib, Pembrolizumab, and Tumor Treating Fields (TTFields) for Second-line Treatment of Glioblastoma | NCT05973903 | GBM | Lenvatinib Pembrolizumab Tumor Treating ... | 18 Years - | Tel Aviv Medical Center | |
| Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775]) | NCT03517449 | Endometrial Neo... | Pembrolizumab Lenvatinib Paclitaxel Doxorubicin | 18 Years - | Eisai Inc. | |
| A Phase II a Study of Lenvatinib, a Multi-targeted Tyrosine Kinase Inhibitor, Combined With Pembrolizumab (PD-1 Inhibitor) for the Treatment of Metastatic Gastroesophageal Cancer Patients Who Have Progressed on First or Subsequent Line Therapies | NCT03321630 | GastroEsophagea... Gastric Cancer | Lenvatinib Pembrolizumab | 18 Years - 100 Years | NYU Langone Health | |
| Lenvatinib Plus Nivolumab Versus Lenvatinib for Advanced Hepatocellular Carcinoma With Hepatitis B Virus Infection | NCT04044651 | Hepatocellular ... | Lenvatinib Nivolumab | 18 Years - | Sun Yat-sen University | |
| Pembrolizumab, Lenvatinib and Chemotherapy After TKIs in NSCLC | NCT04989322 | Nsclc EGFR Activating... EGF-R Positive ... ALK Gene Rearra... ROS1 Gene Rearr... ROS1 Positive N... | Pembrolizumab Lenvatinib Pemetrexed Carboplatin | 18 Years - | The University of Hong Kong | |
| Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma | NCT04401800 | Hepatocellular ... Unresectable He... Metastatic Hepa... | Lenvatinib Tislelizumab | 18 Years - 70 Years | BeiGene | |
| Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian Cancer | NCT02788708 | Fallopian Tube ... Recurrent Ovari... Primary Periton... Recurrent Endom... | Lenvatinib Mesy... Paclitaxel Pharmacological... | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Trial of Lenvatinib Plus PembrolizumAb in Recurrent Gynecological Clear Cell Adenocarcinomas (LARA) | NCT04699071 | Adenocarcinomas Recurrent Gynec... | pembrolizumab a... | 21 Years - 99 Years | National University Hospital, Singapore | |
| An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma | NCT01136967 | Unresectable St... Stage IV Melano... | Lenvatinib | 18 Years - 99 Years | Eisai Inc. | |
| Lenvatinib in Treating Patients With Metastatic or Advanced Pheochromocytoma or Paraganglioma That Cannot Be Removed by Surgery | NCT03008369 | Malignant Adren... Malignant Parag... Metastatic Adre... | Laboratory Biom... Lenvatinib Quality-of-Life... | 18 Years - | Mayo Clinic | |
| Zimberelimab Plus Lenvatinib After Progression on Prior Immune Checkpoint Inhibitors for Advanced Cervical Cancer | NCT05824468 | Cervical Cancer Cervical Carcin... | Zimberelimab Lenvatinib | 18 Years - 75 Years | Sun Yat-sen University | |
| Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009) | NCT04428151 | Squamous Cell C... | Lenvatinib Pembrolizumab Docetaxel Capecitabine Paclitaxel Cetuximab Lenvatinib | 18 Years - | Merck Sharp & Dohme LLC | |
| Microwave Ablation Simultaneously Combined With Lenavatinib for Recurrent Hepatocellular Carcinoma | NCT05444478 | Hepatocellular ... Microwave Ablat... Liver Cancer Lenvatinib Recurrent Tumor | Microwave ablat... Lenvatinib | 18 Years - 75 Years | Sun Yat-sen University | |
| The Efficacy and Safety of Lenvatinib Combined With Sindilimab and Nab-paclitaxel in the First-line Treatment for Recurrent and Metastatic Triple Negative Breast Cancer: a Phase Ib/IIa Clinical Trial. | NCT06140576 | Breast Neoplasm... | Sindilimab Nab-paclitaxel Lenvatinib | 18 Years - 70 Years | Zhejiang Cancer Hospital | |
| AMG510 (Sotorasib) Plus Lenvatinib as Second-line Treatment in Patients With KRASG12C Mutant, Metastatic NSCLC | NCT06068153 | Metastatic Non ... KRAS G12C | Sotorasib Lenvatinib | 18 Years - | ETOP IBCSG Partners Foundation | |
| Second-line Treatment With Serplulimab, Lenvatinib, and Paclitaxel in Advanced Gastric Cancer After Prior Immunotherapy | NCT05585580 | Advanced Gastri... | Serplulimab Lenvatinib Paclitaxel/Pacl... | 18 Years - 75 Years | Qilu Hospital of Shandong University | |
| Neoadjuvant Treatment Associated With Maintenance Therapy by Anti-PD1 Immunotherapy in Patients With Resectable Head and Neck Mucosal Melanoma | NCT03313206 | Head and Neck M... | Pembrolizumab Surgery IMRT Lenvatinib | 18 Years - | Gustave Roussy, Cancer Campus, Grand Paris | |
| Phase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors | NCT04669496 | Intrahepatic Ch... PD1 Antibody Lenvatinib Gemox Chemother... | Neoadjuvant tre... | 18 Years - 70 Years | Shanghai Zhongshan Hospital | |
| Study of TACE Combined With Lenvatinib to Prevent Postoperative Recurrence in Patients With MVI Positive HCC | NCT04911959 | Hepatocellular ... Lenvatinib | Lenvatinib TACE | 18 Years - 75 Years | Second Affiliated Hospital, School of Medicine, Zhejiang University | |
| TACE Combined With Lenvatinib for Unresectable Hepatocellular Carcinoma (Prolong) | NCT04560751 | Carcinoma, Hepa... | Lenvatinib TACE | 18 Years - 75 Years | Zhejiang Cancer Hospital | |
| Lenvatinib Plus Paclitaxel for Patients With Advanced Biliary Tract Cancer Who Failed to Gemcitabine-based Treatment | NCT05170438 | Advanced Biliar... | Lenvatinib Pill... | 20 Years - | National Health Research Institutes, Taiwan | |
| Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib for Patients With Advanced Pancreatic Cancer | NCT05303090 | Pancreatic Duct... | H101 Tislelizumab lenvatinib | 18 Years - | Fudan University | |
| An Open-label, Phase I/II Study of PLENA Regimen in Patients With Unresectable Pancreatic Cancer or BTC | NCT05327582 | Pancreatic Canc... Biliary Tract C... | Durvalumab Lenvatinib Nab paclitaxel | 18 Years - 75 Years | Chinese PLA General Hospital | |
| Lenvatinib and Iodine Therapy in Treating Patients With Radioactive Iodine-Sensitive Differentiated Thyroid Cancer | NCT03506048 | Differentiated ... Thyroid Gland F... Thyroid Gland P... | Lenvatinib | 18 Years - | Emory University | |
| Testing Lenvatinib and Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma and Cutaneous Squamous Cell Carcinoma | NCT03524326 | Head and Neck S... Cutaneous Squam... Head and Neck C... Head and Neck C... | Lenvatinib Pill Lenvatinib Pill Lenvatinib Pill Cetuximab Lenvatinib Pill Lenvatinib Pill | - | Memorial Sloan Kettering Cancer Center | |
| Pembrolizumab and Lenvatinib for Resectable Hepatocellular Carcinoma | NCT05389527 | Carcinoma, Hepa... | Pembrolizumab+L... | 18 Years - | Shanghai Zhongshan Hospital |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
